Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. AD patients with moderate to severe AD who are indicated for treatment with dupilumab~2. Peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy allergic subjects, with a well-documented medical history of reactions after ingestion.Peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy specific immunoglobulin E (IgE) level (Phadia CAP-system) higher than 0.35 kU/L or a skin prick test of at least 3 mm~3. Positive double-blind placebo-controlled Food Challenge (DBPCFC) with an eliciting dose before the last dose~4. Signed Bioday informed consent from subjects~Exclusion Criteria:~1. Subjects reacting objectively to the placebo at screening.~2. Subjects in whom DBCPFC is contra-indicated or in whom DBPCFC is not reliable

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).